COX6C Antibody

How do researchers validate COX6C antibody specificity for techniques like Western blotting (WB) and immunohistochemistry (IHC)?

Validation requires a multi-step approach:

• Knockout controls: Use siRNA-mediated COX6C knockdown in cell lines (e.g., H1299 or H1975 lung adenocarcinoma cells) to confirm loss of signal in WB .

• Cross-reactivity testing: Verify antibody performance across species using recombinant proteins. For example, the H-9 clone (Santa Cruz Biotechnology) detects human, mouse, and rat COX6C , while the 4G4-2A8 clone (Antibodies-Online) is human-specific .

• Epitope mapping: Antibodies targeting residues 1–75 (e.g., ABIN560445) or 34–67 should align with conserved regions in the COX6C structure (77% homology between human and mouse) .

Table 1: Antibody Validation Parameters

What criteria should guide antibody selection for mitochondrial localization studies?

Prioritize antibodies validated for immunofluorescence (IF) and subcellular fractionation:

• Mitochondrial enrichment: Combine COX6C staining with mitochondrial markers (e.g., TOMM20) and counterstain nuclei with DAPI .

• Fixation compatibility: Paraffin-embedded sections require heat-induced epitope retrieval (HIER) for IHC, while frozen tissues may use milder detergents .

• Conjugate compatibility: Phycoerythrin (PE)- or Alexa Fluor®-labeled antibodies improve resolution in multi-channel IF .

How should storage conditions be optimized to preserve COX6C antibody integrity?

• Lyophilized vs. liquid: Reconstituted antibodies (e.g., ABIN560445) require aliquoting to avoid freeze-thaw cycles, with long-term storage at -20°C .

• Buffer composition: PBS (pH 7.4) with 0.09% sodium azide prevents aggregation in conjugated antibodies like HRP-linked H-9 .

What troubleshooting strategies address weak/no signal in COX6C Western blots?

• Mitochondrial enrichment: Isolate mitochondrial fractions via differential centrifugation to concentrate COX6C .

• Blocking optimization: Use 5% non-fat milk for 1 hour to reduce non-specific binding .

• Alternative clones: If H-9 fails, test antibodies targeting different epitopes (e.g., AA 34–67) .

How is COX6C expression quantified in IHC for clinical correlations?

• Scoring system: Use the IHC Profiler plugin in ImageJ to classify staining intensity (0–3+) and calculate H-scores .

• Tissue microarrays (TMAs): Include ≥50 LUAD samples to statistically link COX6C amplification (8q22.2) with survival outcomes .

How can contradictory data on COX6C’s role in apoptosis be resolved?

Studies report both pro-survival and pro-apoptotic effects depending on cellular context:

What protocols enable COX6C antibody use in multiplexed mitochondrial assays?

• Sequential staining: Perform COX6C IHC first, then incubate with antibodies for adjacent complexes (e.g., ATP5A for Complex V) .

• Flow cytometry: Combine FITC-conjugated COX6C with MitoTracker Red to quantify mitochondrial mass in live cells .

Table 2: Multiplex Assay Design

How does COX6C antibody staining inform mitochondrial dynamics in live-cell imaging?

• JC-1 assays: Use COX6C KD cells to correlate mitochondrial membrane potential (ΔΨm) loss (red/green fluorescence ratio ≤1) with fission/fusion imbalances .

• Time-lapse microscopy: Track mitochondrial morphology changes post-transfection with COX6C siRNA over 48 hours .

What computational tools integrate COX6C IHC data with genomic alterations?

• Spatial transcriptomics: Overlay COX6C expression maps with CNV data (8q22.2 amplification) using Visium platforms.

• Survival analysis: Use Cox regression in R to associate H-scores with progression-free survival in TCGA-LUAD cohorts .

How do post-translational modifications (PTMs) affect COX6C antibody binding?

• Phosphorylation screens: Treat lysates with λ-phosphatase to test if epitopes (e.g., AA 1–75) are phosphorylation-dependent .

• Ubiquitination assays: Co-stain with ubiquitin antibodies in proteasome inhibitor-treated cells to detect degradation-resistant COX6C .

Single-cell RNA-seq validation

• Fluorescent barcoding: Pair COX6C IF with oligo-conjugated antibodies (e.g., BD AbSeq) to link protein expression with transcriptomic clusters .

• Drop-out rates: Compare scRNA-seq detection of COX6C mRNA with IHC scores to identify technical false negatives .

CRISPR-Cas9 synergy

• Co-delivery systems: Transfect COX6C gRNAs alongside antibody-conjugated lipid nanoparticles to track editing efficiency via fluorescence .